A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone Dara-VCD Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Brief Summary

Type:
Multiple Myeloma

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT06022939

Study #:
STUDY00160519

Start Date:
May 23, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06022939

View Complete Trial Details & Eligibility at ClinicalTrials.gov